Global Malignant Melanoma Drug Market, Price, Dosage and Clinical Pipeline Outlook 2024

“Global Malignant Melanoma Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024” report highlights:

* Global Malignant Melanoma Drug Market Overview
* Dosage, Price and Patent Insight
* Global Malignant Melanoma Drug Clinical Pipeline: 197 Drugs
* Marketed Malignant Melanoma Drug Clinical Insight: 25 Drugs
* Sales Analysis of Global Melanoma Therapeutics
* Regional Analysis of the Melanoma Drug Market

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-malignant-melanoma-drug-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Malignant Melanoma - Common Cancer with High Mortality
1.1 Prologue to Malignant Melanoma
1.2 Risk Factors Associated with Melanoma
1.3 Overview of Melanoma Diagnosis and Therapy

2. Analysis Regarding the Global Prevalence of Melanoma
2.1 Prevalence in the US
2.2 Prevalence in Europe and Rest of the World

3. Melanoma Market Analysis by Diagnosis and Screening
3.1 Stages of melanoma Diagnosis and Treatment Options
3.2 Cost Analysis of Melanoma Screening

4. Malignant Melanoma Therapy and Cost Analysis by Stage
4.1 Stage 0
4.2 Stage I
4.3 Stage II Melanoma
4.4 Stage III Melanoma
4.5 Stage IV Melanoma
4.6 Recurrent Melanoma

5. Malignant Melanoma Management and Therapy - Cost Analysis by Treatment Modality
5.1 Surgery
5.2 Radiation Therapy
5.3 Chemotherapy
5.3.1 Decarbazine
5.3.2 Temozolomide
5.3.3 Taxol (Paclitaxel and Carboplatin)
5.4 Biological Therapy/Targeted Therapies
5.4.1 T-VEC (Imlygic)
5.4.2 Nivolumab (Opdivo)
5.4.3 Ipilimumab (Yervoy)
5.4.4 Pembrolizumab (Keytruda)
5.4.5 Peginterferon alpha 2-b (Sylatron)
5.4.6 Interleukin-2 (IL-2; Proleukin)
5.5 Inhibitors in Malignant Melanoma Treatment
5.5.1 Vemurafenib (Zelboraf) + Cobimetinib (Cotellic)
5.5.2 Dabrafenib (Tafinlar) + Trametinib (Mekinist)
5.5.3 Vemurafenib (Zelboraf)

6. Sales Analysis of Global Melanoma Therapeutics
6.1 Global- Melanoma Chemotherapy Drug Sales
6.2 Melanoma Targeted Therapy Sales Analysis

7. Malignant Melanoma Therapy - Market Trend and Scope Analysis
7.1 Overview - Screening and Traditional Therapy Market
7.2 Modern Melanoma Therapeutics Market

8. Global Malignant Melanoma Drug Clinical Pipeline Overview

9. Regional Analysis of the Melanoma Drug Market
9.1 North America
9.1.1 US
9.1.2 Canada
9.2 Europe
9.3 Asia Pacific
9.3.1 Japan
9.3.2 China
9.3.3 Australia
9.4 Middle East and Africa (MEA)

10. Global Melanoma Drug Market Dynamics
10.1 Driving Factors of the Malignant Melanoma Drug Market
10.2 Restraining Factors of the Melanoma Drug Market

11. Future Forecast Regarding the Malignant Melanoma Drug Market

12. Global Malignant Melanoma Drug Clinical Pipeline by Company and Phase
12.1 Unknown
12.2 Research
12.3 Preclinical
12.4 Clinical
12.5 Phase-I
12.6 Phase-I/II
12.7 Phase-II
12.8 Phase-II/III
12.9 Phase-III
12.10 Preregistration
12.11 Registered

13. Marketed Malignant Melanoma Drug Clinical Insight

14. Competitive Analysis
14.1 AVAX Technologies
14.2 Biogen Idec
14.3 BioVex
14.4 Bristol-Myers Squibb
14.5 Chiron
14.6 Enzon Pharmaceuticals
14.7 GlaxoSmithKline
14.8 Lorus Therapeutics
14.9 Medarex
14.10 Merck
14.11 Ono Pharmaceutical
14.12 Plexxikon
14.13 Reliance Life Sciences
14.14 Roche

Figure 1-1: Historical Timeline of Melanoma
Figure 1-2: Malignant Melanoma - Risk Factors
Figure 1-3: Difference between Normal Skin Lesions and Melanoma
Figure 1-4: Melanoma Development in Action
Figure 1-5: Melanoma- Biopsy Types
Figure 1-6: Biopsy Techniques used for the Diagnosis of melanoma
Figure 2-1: US - Melanoma Prevalence by Gender (Number of patients), 2018
Figure 2-2: 5 Year Survival Rate- by Stage of Therapy (%)
Figure 2-3: Europe - Regional Mortality by Melanoma (number of Deaths per 100,000 patients), 2012-2016
Figure 2-4: Global- Melanoma Prevalence (per 100,000 Individuals), 2016
Figure 3-1: Cost Analysis - Melanoma Screening Cost (US$), 2018
Figure 3-2: Australia - Melanoma Management and Therapy Cost Analysis (US$/Patient), 2018
Figure 4-1: Comparative Price Analysis- by Body Part affected by Melanoma, 2018
Figure 4-2: Melanoma Stage 0 - Estimated Treatment Cost (US$), 2018
Figure 4-3: Stage I - Estimated Treatment Cost (US$), 2018
Figure 4-4: Melanoma Treatment Efficacy (Stage II) by Treatment Modality (%), 2018
Figure 4-5: Stage II -Estimated Cost Analysis by Technique (US$), 2018
Figure 4-6: Stage III/IV Treatment Modality Approach
Figure 5-1: Surgery-Average Cost Analysis Range by Stage (US$/Patient), 2018
Figure 5-2: Surgery - Average Cost Analysis (US$), 2016
Figure 5-3: Radiation Therapy - Average Cost Analysis by Melanoma Location (US$), 2018
Figure 5-4: Dosage Analysis - Decarbazine and Temozolomide(mg/kg)
Figure 5-5: Price Analysis - Decarbazine and Temozolomide(US$/100mg), 2018
Figure 5-6: Temozolomide - Price Analysis (US$), 2018
Figure 5-7: Temozolomide - Price Analysis (US$/mg), 2018
Figure 5-8: Cost Analysis - Melanoma Targeted Therapy (US$/Month), 2018
Figure 5-9: T-VEC: Mechanism of Action
Figure 5-10:T-VEC- Dosage Analysis(ml/ Plaque Forming Unit*)
Figure 5-11: Imlygic - Vial and Therapy Cost Analysis (US$), 2018
Figure 5-12: Nivolumab + Iplimumab-Dosage Analysis (mg)
Figure 5-13: Yervoy- Mechanism of Action in Melanoma Therapy
Figure 5-14: Nivolumab and Ipilimumab- Drug Price Analysis (US$/mg), 2018
Figure 5-15: Keytruda -Dosage Analysis (mg/kg)
Figure 5-16: Sylatron - Dosage Analysis (mcg/kg body weight/week)
Figure 5-17: Interleukin-2 Action Mechanism
Figure 5-18: Zelboraf and Cobimetinib - Dosage Analysis (mg)
Figure 5-19: Zelboraf and Cotellic - Price Analysis (US$/Month), 2018
Figure 5-20: Tafinlar- Dosage Analysis (mg Twice Daily)
Figure 5-21: Mekinist - Dosage Analysis (mg once daily)
Figure 6-1: Global - Melanoma Chemotherapeutics Sales (US$ Million), 2014-2016
Figure 6-2: Global - Melanoma Biological Therapeutics Sales (US$ Million), 2015-2016
Figure 7-1: Global - Melanoma Market Segmentation by Diagnosis and Therapy (%), 2018
Figure 7-2: Global- Melanoma Diagnosis Market Forecast (US$ Billion), 2016-2024
Figure 7-3: Global - Melanoma Chemotherapy Drug Sales Forecast (US$ Billion), 2018-2024
Figure 7-4: Global - Melanoma Surgery Market Forecast (US$ Million), 2018-2024
Figure 7-5: Global- Radiation Melanoma Therapy Forecast (US$ Million), 2018-2024
Figure 7-6: Global - Melanoma Targeted Therapy Market Forecast, 2016-2024
Figure 8-1: Global - Malignant Melanoma Pipeline by Phase (%), 2018 till 2024
Figure 8-2: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
Figure 8-3: Global - Malignant Melanoma Pipeline by Phase (%),2018 till 2024
Figure 8-4: Global - Malignant Melanoma Pipeline by Phase (Number), 2018 till 2024
Figure 9-1: US - Melanoma Therapeutics Market Forecast (US$ Billion), 2016-2024
Figure 9-2: Canada- Melanoma Therapeutics Market Forecast (US$ Million), 2016-2024
Figure 9-3: Europe - Treatment Modality Used in Melanoma Therapy, 2016-2017
Figure 10-1: Driving Factors of the Global Melanoma Drug Market
Figure 10-2: Melanoma Drug Market - Growth Restraining Factors



Table 3-1: Melanoma Stage, Description and Available Treatment Options

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.